663 related articles for article (PubMed ID: 31212145)
1. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
2. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy with cell free DNA: new horizons for prostate cancer.
Ponti G; Maccaferri M; Percesepe A; Tomasi A; Ozben T
Crit Rev Clin Lab Sci; 2021 Jan; 58(1):60-76. PubMed ID: 32805148
[TBL] [Abstract][Full Text] [Related]
4. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
5. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
6. Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker.
Ponti G; Maccaferri M; Mandrioli M; Manfredini M; Micali S; Cotugno M; Bianchi G; Ozben T; Pellacani G; Del Prete C; Tomasi A
Pathol Oncol Res; 2018 Oct; 24(4):941-945. PubMed ID: 29730802
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
8. Urine-Based Liquid Biopsy for Nonurological Cancers.
Jain S; Lin SY; Song W; Su YH
Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
10. When Tissue Is the Issue: Expanding Cell-Free DNA "Liquid Biopsies" to Supernatants and Nonplasma Biofluids.
Paulson V; Konnick EQ; Lockwood CH
Clin Lab Med; 2022 Sep; 42(3):485-496. PubMed ID: 36150825
[TBL] [Abstract][Full Text] [Related]
11. Liquid Biopsy: A New Tool in Oncology.
Costa JL; Schmitt FC
Acta Cytol; 2019; 63(6):448. PubMed ID: 31266005
[No Abstract] [Full Text] [Related]
12. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
13. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA: Applications in Different Diseases.
Ranucci R
Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419
[TBL] [Abstract][Full Text] [Related]
15. Size distribution of cell-free DNA in oncology.
Udomruk S; Orrapin S; Pruksakorn D; Chaiyawat P
Crit Rev Oncol Hematol; 2021 Oct; 166():103455. PubMed ID: 34464717
[TBL] [Abstract][Full Text] [Related]
16. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
[TBL] [Abstract][Full Text] [Related]
17. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
19. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
20. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
